文献速递肾移植

自动化尿液趋化因子检测无创诊断肾移植排斥的前瞻性队列研究

Automated Urinary Chemokine Assays for Noninvasive Detection of Kidney Transplant Rejection: A Prospective Cohort Study.
PubMed 文献 · Am J Kidney Dis · 2023-09-29

该单中心前瞻性队列研究分析了622例肾移植的1559份活检配对尿液样本,评估尿液CXCL9和CXCL10整合临床信息后诊断急性排斥的性能,整合模型ROC曲线下面积为81.3%(95%CI 77.6-85.0),外部验证性能相似,可减少活检数量。

要点

  • 尿液CXCL9和CXCL10与常规临床标志物整合模型对急性排斥有较高诊断价值(AUC 81.3%)。
  • 当预测排斥风险低于10%时,整合模型每100例患者可避免59次方案活检。
  • 外部验证队列中整合模型性能相似,但研究为横断面性质,无法评估随时间变化或预测未来排斥。

核心结论

  • 尿液趋化因子与临床标志物整合模型可用于无创监测肾移植排斥,可能减少活检数量。
  • 尿液趋化因子可能是有用的无创生物标志物,需进一步前瞻性随机试验明确其在指导临床诊疗和活检中的作用。

研究设计与样本

  • 单中心前瞻性队列研究,纳入2013年4月至2019年7月在比利时单中心进行的622例肾移植的1559份活检配对尿液样本。
  • 外部验证使用986份活检配对尿液样本。
  • 使用自动化免疫分析平台定量尿液CXCL9和CXCL10,并以尿肌酐归一化。
  • 将尿液趋化因子与常规临床标志物(估算肾小球滤过率、供者特异性抗体、多瘤病毒血症)整合入多变量模型(整合模型),并与Banff分类的组织诊断比较。

主要发现

  • 整合模型检测急性排斥(n=150)的ROC曲线下面积为81.3%(95%CI 77.6-85.0)。
  • 当预测排斥风险低于10%时,整合模型每100例患者可帮助避免59次方案活检。
  • 整合模型在外部验证队列中性能相似。

关键数值与推荐

  • 急性排斥定义为根据Banff分类在肾活检中检测到。
  • 整合模型检测急性排斥的ROC曲线下面积为81.3%(95%CI 77.6-85.0)。
  • 预测排斥风险低于10%时,每100例患者可避免59次方案活检。

临床怎么用

  • 尿液趋化因子与临床信息整合模型可用于无创监测肾移植排斥,可能指导活检实践并减少肾移植活检需求。
  • 尿液趋化因子在临床实施前需明确使用场景并与临床信息整合。
  • 其作用需进一步前瞻性随机试验研究以明确在指导临床诊疗和活检中的应用。

局限性

  • 研究的横断面性质无法研究随时间的变化和预测未来排斥。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Prior studies have demonstrated the diagnostic potential of urinary chemokines C-X-C motif ligand 9 (CXCL9) and CXCL10 for kidney transplant rejection. However, their benefit in addition to clinical information has not been demonstrated. We evaluated the diagnostic performance for detecting acute rejection of urinary CXCL9 and CXCL10 when integrated with clinical information. STUDY DESIGN: Single-center prospective cohort study. SETTING & PARTICIPANTS: We analyzed 1,559 biopsy-paired urinary samples from 622 kidney transplants performed between April 2013 and July 2019 at a single transplant center in Belgium. External validation was performed in 986 biopsy-paired urinary samples. TESTS COMPARED: We quantified urinary CXCL9 (uCXCL9) and CXCL10 (uCXCL10) using an automated immunoassay platform and normalized the values to urinary creatinine. Urinary chemokines were incorporated into a multivariable model with routine clinical markers (estimated glomerular filtration rate, donor-specific antibodies, and polyoma viremia) (integrated model). This model was then compared with the tissue diagnosis according to the Banff classification for acute rejection. OUTCOME: Acute rejection detected on kidney biopsy using the Banff classification. RESULTS: Chemokines integrated with routine clinical markers had high diagnostic value for detection of acute rejection (n=150) (receiver operating characteristic area under the curve 81.3% [95% CI, 77.6-85.0]). The integrated model would help avoid 59 protocol biopsies per 100 patients when the risk for rejection is predicted to be below 10%. The performance of the integrated model was similar in the external validation cohort. LIMITATIONS: The cross-sectional nature obviates investigating the evolution over time and prediction of future rejection. CONCLUSIONS: The use of an integrated model of urinary chemokines and clinical markers for noninvasive monitoring of rejection could enable a reduction in the number of biopsies. Urinary chemokines may be useful noninvasive biomarkers whose use should be further studied in prospective randomized trials to clarify their role in guiding clinical care and the use of biopsies to detect rejection after kidney transplantation. PLAIN-LANGUAGE SUMMARY: Urinary chemokines CXCL9 and CXCL10 have been suggested to be good noninvasive biomarkers of kidney transplant rejection. However, defining a context of use and integration with clinical information is necessary before clinical implementation can begin. In this study, we demonstrated that urinary chemokines CXCL9 and CXCL10, together with clinical information, have substantial diagnostic accuracy for the detection of acute kidney transplant rejection. Application of urinary chemokines together with clinical information may guide biopsy practices following kidney transplantation and potentially reduce the need for kidney transplant biopsies.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Van Loon E, Tinel C, de Loor H, et al. Automated Urinary Chemokine Assays for Noninvasive Detection of Kidney Transplant Rejection: A Prospective Cohort Study. Am J Kidney Dis. 2023. PMID: 37777058. doi:10.1053/j.ajkd.2023.07.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。